Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin vs Nebulized Dexmedetomidine for Hemodynamic Response
NCT06935292Phase 3Not yet recruiting
- Sponsor
- Tanta University
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in hemodynamic instability comparing Dexmedetomidine group with Melatonin group (2 arms). Primary endpoint: Change in Heart Rate up to 2 hours. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
melatonindexmedetomidine
03
Conditions
hemodynamic instability
Beyond the preview
Go deeper on NCT06935292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06935292.